Capstone Therapeutics Announces Chrysalin(r) (TP508, Rusalatide Acetate) Scientific Abstracts to be Presented At the American Society for Cell Biology 48th Annual Meeting; Studies Characterize Integrin Interaction and Biologic Activity

Published: Dec 15, 2008

TEMPE, Ariz., Dec. 15, 2008 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the publication of several abstracts characterizing the science of its novel thrombin peptide Chrysalin(r) (TP508 or rusalatide acetate). The abstracts being presented at the American Society for Cell Biology 48th Annual Meeting (December 13 - 17, 2008 - San Francisco, CA) provide new support for the mechanism of action and observed effects of TP508.

Back to news